biotech workforce

Actionable Insights Powered by AI

Adaptimmune Expects To Cut 62% of Staff After Cell Therapy Asset Sale

Adaptimmune; layoffs; cell therapy sale; US WorldMeds; restructuring; biotech workforce reduction; TECELRA; lete-cel; afami-cel; uza-cel